GSK and Genmab Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s Lymphoma

10-Sep-2010 - Denmark

GlaxoSmithKline (GSK) and Genmab A/S announced the start of a Phase III study in patients with indolent B-cell non-Hodgkin’s lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen. Under the terms of Genmab’s collaboration with GlaxoSmithKline (GSK), Genmab will receive a milestone payment of approximately DKK 116 million (approximately USD 20 million), triggered by the treatment of the first patient in the study.

A total of 338 patients in this open label study will be randomized to receive either ofatumumab in addition to bendamustine or bendamustine alone. The primary endpoint of the study is progression free survival. Patients in the bendamustine monotherapy group will have the opportunity to receive ofatumumab if their lymphoma progresses.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances